Financial Comparison: Vivos (OTCMKTS:RDGL) vs. Quoin Pharmaceuticals (NASDAQ:QNRX)

Vivos (OTCMKTS:RDGL – Get Rating) and Quoin Pharmaceuticals (NASDAQ:QNRX – Get Rating) are both small-cap finance companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Institutional & Insider Ownership

12.1% of Quoin Pharmaceuticals shares are held by institutional investors. 18.5% of Vivos shares are held by company insiders. Comparatively, 36.6% of Quoin Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Vivos and Quoin Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivos	-6,586.84%	N/A	-159.23%
Quoin Pharmaceuticals	N/A	-533.98%	-102.01%

Analyst Recommendations

This is a summary of current ratings and target prices for Vivos and Quoin Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos	0	0	0	0	N/A
Quoin Pharmaceuticals	0	1	1	0	2.50

Quoin Pharmaceuticals has a consensus target price of $17.50, suggesting a potential upside of 3,622.61%. Given Quoin Pharmaceuticals’ higher possible upside, analysts plainly believe Quoin Pharmaceuticals is more favorable than Vivos.

Volatility and Risk

Vivos has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500. Comparatively, Quoin Pharmaceuticals has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500.

Valuation & Earnings

This table compares Vivos and Quoin Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos	$40,000.00	569.17	-$2.47 million	N/A	N/A
Quoin Pharmaceuticals	N/A	N/A	-$9.45 million	($7.09)	-0.07

Vivos has higher revenue and earnings than Quoin Pharmaceuticals.

Summary

Quoin Pharmaceuticals beats Vivos on 6 of the 10 factors compared between the two stocks.

About Vivos

(Get Rating)

Vivos, Inc. is a radiation oncology medical device company. It is engaged in the development of its yttrium-90 based brachytherapy device, RadioGel, for the treatment of non-resectable tumors. The firm’s product, RadioGel, is an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals. The company was founded by James C. Katzaroff on December 23, 1994 and is headquartered in Richland, WA.

About Quoin Pharmaceuticals

(Get Rating)

Quoin Pharmaceuticals Ltd. is a specialty pharmaceutical company engaged in the development of therapeutic products for the treatment of rare and orphan diseases. The company was founded on March 5, 2018 and is headquartered in Kefar Sava, Israel.